Outpatient Care Less Efficient for Neonatal Abstinence Syndrome

Share this content:
Outpatient Care Less Efficient for Neonatal Abstinence Syndrome
Outpatient Care Less Efficient for Neonatal Abstinence Syndrome

FRIDAY, June 22, 2018 (HealthDay News) -- In infants with neonatal abstinence syndrome (NAS) outpatient pharmacotherapy is associated with longer length of therapy and higher rates of emergency department utilization than exclusive inpatient treatment, according to a study published online May 10 in The Journal of Pediatrics.

Faouzi I. Maalouf, M.D., from American University of Beirut, and colleagues performed a retrospective cohort study to compare differences in health care utilization in 736 infants with NAS who were either treated exclusively with inpatient pharmacotherapy or discharged on outpatient pharmacotherapy. The infants were enrolled in the Tennessee Medicaid program, and the researchers used administrative and vital records data from 2009 to 2011.

The researchers found that 72.3 percent of infants were treated with pharmacotherapy, and of those, 45.5 percent were discharged home on outpatient medications. Initial hospital length of stay was shorter (11 versus 23 days) and length of therapy was longer (60 versus 19 days; adjusted incidence rate ratio, 2.84) for infants discharged on outpatient pharmacotherapy. Within six months of discharge, infants discharged on outpatient pharmacotherapy had a greater number of emergency department visits (adjusted odds ratio, 1.52) compared with those treated as inpatients alone after adjustment for potential confounding variables.

"Future research should focus on improving the efficiency of NAS management while minimizing postdischarge complications," write the authors.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »